Blog

The Economist: Novel vaccines performed well

March 23, 2021

Andrey Zarur, CEO of GreenLight Biosciences, is mentioned in The Economist in a piece looking at the performance of novel vaccines.

Andrey Zarur, CEO of GreenLight Biosciences, is mentioned in The Economist in a piece looking at the performance of novel vaccines. He explains the potential for a vaccine production network in poorer regions of the world. An extract is below:

Andrey Zarur, the boss of GreenLight, a biotech company based in Boston, is one of those seized by the possibilities. GreenLight intends to use production processes similar to those used by the vaccine-makers to produce a different sort of rna molecule which can be used as a pesticide targeted against the Colorado Beetle. The project will make sense only if it can bring costs down dramatically. If it works, though, it will significantly increase the ability to send purposeful genetic messages straight to distant cells.

But GreenLight is also exploring the idea of an mrna vaccine-production network that serves poorer regions directly, as are others. “It is plausible to consider building factories on different continents,” says Mr Sahin of BioNTech, “and thereby enable independence of the region from global supply.” If need be, such plants could be used to respond to regional changes in the virus’s make-up, making the vaccine most needed right there, right then. In the event that does not prove necessary, making mrna vaccines closer to the point of use could still have other advantages, such as security of supply.


More of Greenlight Bioscience in the news: